U
UroMems
Developing an active implantable medical device which compensates for sphincter insufficiency
About UroMems
UroMems is a pioneering startup that is revolutionizing the medical industry with its innovative technology. The company specializes in developing smart, active implantable medical devices designed to treat stress urinary incontinence (SUI), a condition that affects both men and women. SUI can significantly impact a person's quality of life, and UroMems' technology aims to provide an efficient and personalized solution to this problem.
Read full description
The company's flagship product, UroActive™, is a testament to its commitment to leveraging the latest technological advancements in embedded systems and micro-technologies. This product is designed to automatically adjust to each patient's unique needs, providing an improved experience and a better quality of life.
UroMems operates in the global medical device market, serving a broad range of clients, including hospitals, clinics, and healthcare providers. The company's business model revolves around the development, production, and sale of its innovative medical devices. The revenue is generated from the sales of these devices to healthcare providers who then offer the treatment to their patients.
Founded in 2011 by a team of experts with multiple patents to their name, UroMems has positioned itself as a leader in the development of smart implantable medical devices. The company's groundbreaking technology and commitment to improving patient outcomes underscore its potential for growth in the medical device industry.
At a glance
- Status
- Operational
- Founded
- 2011
- Headquarters
- Eybens, France
- Employees
- 90
- Open positions
- 6
- Dealroom signal
- 91.8/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, EIC, EIC Fund, biotech medtech and e-health, Observatoire Deeptech, Horizon Europe
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning UroMems.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | May 2026 | $60M | $240M | Ajax Health | ↗ |
| SERIES COther financing | Jun 2024 | $48M | $194M | b2venture · Financiere Arbevel · Hil-Invent · EIC Fund | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for UroMems is 3.8K monthly website visits, up 52% over the last three months. UroMems's team grew 20% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
European Innovation Council
Series A13 investors entered at this stage
Series B and later2 investors entered at this stage
Crédit Mutuel Innovation
Ajax Health
Other known investors4 additional known investors
Grenoble Institute of Technology - Grenoble INP
French National Centre for Scientific Research - CNRS
Grenoble Alpes University
VetAgro Sup – National Institute for Veterinary and Agricultural Sciences
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about UroMems on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See UroMems’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.